Print page
Email page
Download PDF
« Previous Release | Next Release »
Highlights: Second quarter revenues increased 33% to $7.9 million 796 TranS1 procedures performed globally in the quarter Gross margin was 80.9% for the quarter GAAP loss per share was $0.33 for the quarter Non-GAAP loss per share was $0.28 for the quarter
WILMINGTON, N.C., July 30, 2009 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease and instability affecting the lower lumbar region of the spine, today announced its financial results for the second quarter ended June 30, 2009.
Revenues were $7.9 million in the second quarter of 2009, representing a 33% increase over revenues of $6.0 million in the second quarter of 2008. Gross margin was 80.9% in the second quarter of 2009, which was consistent with the second quarter of 2008.
Operating expenses were $13.3 million in the second quarter of 2009 compared to $10.8 million in the second quarter of 2008. The increase in operating expenses is primarily attributable to an increase in sales and marketing costs as a result of the continued expansion of the direct sales force, increased commissions as a result of increased sales and increased spending for research and development.
Net loss was $6.8 million and $5.3 million for the quarters ended June 30, 2009 and 2008, respectively. GAAP net loss per common share was $0.33 in the second quarter of 2009 compared to a net loss per share of $0.26 in the second quarter of 2008.
For the quarters ended June 30, 2009 and 2008, on a non-GAAP basis adjusting for non-cash stock compensation expense, net loss per common share was $0.28 and $0.20, respectively.
Cash, cash-equivalents and investments were $66.5 million as of June 30, 2009.
"Our results this quarter were impacted by increased concerns and confusion in the marketplace surrounding reimbursement for our AxiaLIF procedure, which we are addressing with increased education and support resources for our current and prospective surgeon users," said Rick Randall, President and CEO of TranS1. "We remain confident in our products, clinical benefits and prospects for future growth as the market for minimally invasive spine surgery continues to expand."
Conference Call
TranS1 will host a conference call today at 4:30 pm ET to discuss its second quarter financial results. To listen to the conference call on your telephone, please dial 888-228-5279 for domestic callers and 913-312-1520 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or the subsequent archived recording, visit the TranS1 website at www.trans1.com under the investor relations section.
Non-GAAP Measures
Management uses certain non-GAAP financial measures such as non-GAAP net loss and net loss per share, which exclude stock based compensation. This non-GAAP presentation is given in part to enhance the understanding of the company's historical financial performance and comparability between periods. The company believes that the non-GAAP presentation to exclude stock-based compensation is relevant and useful information that will be widely used by investors and analysts. Accordingly, the company is disclosing this information to permit additional analysis of the company's performance. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. A reconciliation of the GAAP financial measures to the comparable non-GAAP financial measure is included below.
About TranS1 Inc.
TranS1 is a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease and instability affecting the lower lumbar region of the spine. TranS1 currently markets two single-level fusion products, the AxiaLIF(r) and the AxiaLIF 360(tm), and a two-level fusion product, the AxiaLIF 2L(tm), in the US and Europe. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit www.trans1.com.
Forward-Looking Statements
This press release includes forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. These risks and uncertainties include, among other things, risks associated with the adoption of a new technology by spine surgeons, product development efforts, regulatory requirements, maintenance and prosecution of adequate intellectual property protection and other economic and competitive factors. These forward-looking statements are based on the company's expectations as of the date of this press release and the company undertakes no obligation to update information provided in this press release. For a discussion of risks and uncertainties associated with TranS1's business, please review the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2008.
TranS1 Inc.
Statements of Operations
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
------------------- -------------------
2009 2008 2009 2008
-------- -------- -------- --------
Revenue $ 7,938 $ 5,951 $ 16,616 $ 11,929
Cost of revenue 1,515 1,137 3,057 2,175
-------- -------- -------- --------
Gross profit 6,423 4,814 13,559 9,754
-------- -------- -------- --------
Operating expenses:
Research and development 2,359 1,211 3,685 2,331
Sales and marketing 8,943 7,200 18,093 12,898
General and administrative 1,991 2,390 4,031 3,891
-------- -------- -------- --------
Total operating expenses 13,293 10,801 25,809 19,120
-------- -------- -------- --------
Operating loss (6,870) (5,987) (12,250) (9,366)
Interest income 111 688 328 1,628
-------- -------- -------- --------
Net loss $ (6,759) $ (5,299) $(11,922) $ (7,738)
======== ======== ======== ========
Net loss per common share
- basic and diluted $ (0.33) $ (0.26) $ (0.58) $ (0.39)
======== ======== ======== ========
Weighted average common
shares outstanding -
basic and diluted 20,590 20,212 20,571 20,071
======== ======== ======== ========
Stock-based compensation
is included in operating
expenses in the
following categories:
Cost of revenue $ 18 $ 13 $ 37 $ 27
Research and development 57 204 101 295
Sales and marketing 387 600 775 874
General and administrative 481 515 674 658
-------- -------- -------- --------
$ 943 $ 1,332 $ 1,587 $ 1,854
======== ======== ======== ========
Reconciliation of Quarterly Results
(in thousands, except per share amounts)
(Unaudited) 2009 2008
-------- --------
GAAP net loss $ (6,759) $ (5,299)
Stock based compensation 943 1,332
-------- --------
Non-GAAP net loss $ (5,816) $ (3,967)
======== ========
Shares used in computing GAAP and non-GAAP
loss per share 20,590 20,212
======== ========
Non-GAAP loss per share $ (0.28) $ (0.20)
======== ========
Reconciliation of Year-To-Date Results
(in thousands, except per share amounts)
(Unaudited) 2009 2008
-------- --------
GAAP net loss $(11,922) $ (7,738)
Stock based compensation 1,587 1,854
-------- --------
Non-GAAP net loss $(10,335) $ (5,884)
======== ========
Shares used in computing GAAP and non-GAAP
loss per share 20,571 20,071
======== ========
Non-GAAP loss per share $ (0.50) $ (0.29)
======== ========
TranS1 Inc.
Balance Sheets
(in thousands)
(Unaudited)
June 30, Dec. 31,
2009 2008
--------- ---------
Assets
Current assets:
Cash and cash equivalents $ 29,207 $ 42,051
Short-term investments 37,275 35,215
Accounts receivable, net 4,707 4,812
Inventory 7,346 6,369
Prepaid expenses and other assets 547 632
--------- ---------
Total current assets 79,082 89,079
Property and equipment, net 1,374 1,412
--------- ---------
Total assets $ 80,456 $ 90,491
========= =========
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 3,099 $ 2,896
Accrued expenses 2,021 2,009
--------- ---------
Total current liabilities 5,120 4,905
--------- ---------
Stockholders' equity
Common stock 2 2
Additional paid-in capital 135,175 133,507
Accumulated other comprehensive income 4 --
Accumulated deficit (59,845) (47,923)
--------- ---------
Total stockholders' equity 75,336 85,586
--------- ---------
Total liabilities and
stockholders' equity $ 80,456 $ 90,491
========= =========
TranS1 Inc.
Statements of Cash Flows
(in thousands)
(Unaudited)
Six Months Ended
--------------------
June 30,
2009 2008
-------- --------
Cash flows from operating activities:
Net loss $(11,922) $ (7,738)
Adjustments to reconcile net loss to net
cash used in operating activities
Depreciation 448 369
Stock-based compensation 1,587 1,854
Allowance for excess and obsolete
inventory 383 34
Provision for bad debts 45 66
Changes in operating assets and
liabilities:
(Increase) decrease in accounts
receivable 60 (615)
(Increase) decrease in inventory (1,360) 27
(Increase) decrease in prepaid
expenses 85 235
Increase (decrease) in accounts
payable 203 386
Increase (decrease) in accrued
expenses 12 (251)
-------- --------
Net cash used in operating activities (10,459) (5,633)
-------- --------
Cash flows from investing activities:
Purchase of property and equipment (410) (618)
Purchases of investments (33,922) (41,288)
Sales and maturities of short-term
investments 31,862 34,791
-------- --------
Net cash provided by (used in) investing
activities (2,470) (7,115)
-------- --------
Cash flows from financing activities:
Proceeds from issuance of common stock 85 121
-------- --------
Net cash provided by (used in) financing
activities 85 121
-------- --------
Net increase (decrease) in cash and cash
equivalents (12,844) (12,627)
Cash and cash equivalents, beginning
of period 42,051 64,676
-------- --------
Cash and cash equivalents, end of period $ 29,207 $ 52,049
======== ========
CONTACT: TranS1 Inc.
Investors:
Michael Luetkemeyer, Chief Financial Officer
910-332-1700
Westwicke Partners
Mark Klausner
443-213-0501
mark.klausner@westwicke.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.